Role of irradiation in management of synovial sarcoma

St. Jude Children's Research Hospital experience

James Fontanesi, Alberto S. Pappo, David M. Parham, Craig A. Hurwitz, Bhaskar N. Rao, Xiaolong Luo, Larry E. Kun, Charles B. Pratt

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The role of irradiation in the management of synovial sarcoma (SS) in pediatric patients is evaluated. The review covers all children seen at St. Jude Children's Research Hospital between May 1969 and December 1992 with the diagnosis of soft tissue sarcoma, of the 37 patients with the subtype SS, 16 received irradiation for the management of primary site disease. There were four IRS Group I, six Group II, four Group III, and two Group IV patients receiving irradiation. Tumor grade included seven Grade II and nine Grade III lesions. TMN staging identified eight T1 and eight T2 lesions. Follow-up has ranged from 14 to 117 months (med = 33 months). All IRS Group I patients had documented local control. Five of six IRS Group II and 4/4 Group III patients have had documented local control at last follow-up. IRS Group IV patients had either local control tumor stabilization (n = 1) or evidence of tumor regression (n = 1) at autopsy. Complications following irradiation include wound dehiscence (n = 1), surgery to revise a painful scar (n = 1) extremity length discrepancy (n = 2), and femoral head avascular necrosis (n = 1). At last follow-up, 10 of 14 patients receiving curative intent irradiation remain alive. This review indicates questionable benefit to the addition of irradiation for patients with adequate surgical resection and having 'good' tumor characteristics (Grade I, II; IRS Group I, TMN T(1A), T(1B)). For lesions that have had incomplete resection or partial response to chemotherapy, there is evidence that irradiation may provide durable local control. The role of irradiation in those patients with IRS Group IV disease is at present confined to palliative roles until the time when more effective chemotherapy will mandate the decision to treat primary disease for curative measures.

Original languageEnglish (US)
Pages (from-to)264-267
Number of pages4
JournalMedical and Pediatric Oncology
Volume26
Issue number4
DOIs
StatePublished - Apr 1 1996

Fingerprint

Synovial Sarcoma
Research
Sarcoma 37
Neoplasms
Femur Head Necrosis
Drug Therapy
Sarcoma
Cicatrix
Autopsy
Extremities
Pediatrics

Keywords

  • irradiation
  • soft tissue sarcoma
  • synovial sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Role of irradiation in management of synovial sarcoma : St. Jude Children's Research Hospital experience. / Fontanesi, James; Pappo, Alberto S.; Parham, David M.; Hurwitz, Craig A.; Rao, Bhaskar N.; Luo, Xiaolong; Kun, Larry E.; Pratt, Charles B.

In: Medical and Pediatric Oncology, Vol. 26, No. 4, 01.04.1996, p. 264-267.

Research output: Contribution to journalArticle

Fontanesi, James ; Pappo, Alberto S. ; Parham, David M. ; Hurwitz, Craig A. ; Rao, Bhaskar N. ; Luo, Xiaolong ; Kun, Larry E. ; Pratt, Charles B. / Role of irradiation in management of synovial sarcoma : St. Jude Children's Research Hospital experience. In: Medical and Pediatric Oncology. 1996 ; Vol. 26, No. 4. pp. 264-267.
@article{e39e248ff08f416c84bce74ff526a495,
title = "Role of irradiation in management of synovial sarcoma: St. Jude Children's Research Hospital experience",
abstract = "The role of irradiation in the management of synovial sarcoma (SS) in pediatric patients is evaluated. The review covers all children seen at St. Jude Children's Research Hospital between May 1969 and December 1992 with the diagnosis of soft tissue sarcoma, of the 37 patients with the subtype SS, 16 received irradiation for the management of primary site disease. There were four IRS Group I, six Group II, four Group III, and two Group IV patients receiving irradiation. Tumor grade included seven Grade II and nine Grade III lesions. TMN staging identified eight T1 and eight T2 lesions. Follow-up has ranged from 14 to 117 months (med = 33 months). All IRS Group I patients had documented local control. Five of six IRS Group II and 4/4 Group III patients have had documented local control at last follow-up. IRS Group IV patients had either local control tumor stabilization (n = 1) or evidence of tumor regression (n = 1) at autopsy. Complications following irradiation include wound dehiscence (n = 1), surgery to revise a painful scar (n = 1) extremity length discrepancy (n = 2), and femoral head avascular necrosis (n = 1). At last follow-up, 10 of 14 patients receiving curative intent irradiation remain alive. This review indicates questionable benefit to the addition of irradiation for patients with adequate surgical resection and having 'good' tumor characteristics (Grade I, II; IRS Group I, TMN T(1A), T(1B)). For lesions that have had incomplete resection or partial response to chemotherapy, there is evidence that irradiation may provide durable local control. The role of irradiation in those patients with IRS Group IV disease is at present confined to palliative roles until the time when more effective chemotherapy will mandate the decision to treat primary disease for curative measures.",
keywords = "irradiation, soft tissue sarcoma, synovial sarcoma",
author = "James Fontanesi and Pappo, {Alberto S.} and Parham, {David M.} and Hurwitz, {Craig A.} and Rao, {Bhaskar N.} and Xiaolong Luo and Kun, {Larry E.} and Pratt, {Charles B.}",
year = "1996",
month = "4",
day = "1",
doi = "10.1002/(SICI)1096-911X(199604)26:4<264::AID-MPO9>3.0.CO;2-H",
language = "English (US)",
volume = "26",
pages = "264--267",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Role of irradiation in management of synovial sarcoma

T2 - St. Jude Children's Research Hospital experience

AU - Fontanesi, James

AU - Pappo, Alberto S.

AU - Parham, David M.

AU - Hurwitz, Craig A.

AU - Rao, Bhaskar N.

AU - Luo, Xiaolong

AU - Kun, Larry E.

AU - Pratt, Charles B.

PY - 1996/4/1

Y1 - 1996/4/1

N2 - The role of irradiation in the management of synovial sarcoma (SS) in pediatric patients is evaluated. The review covers all children seen at St. Jude Children's Research Hospital between May 1969 and December 1992 with the diagnosis of soft tissue sarcoma, of the 37 patients with the subtype SS, 16 received irradiation for the management of primary site disease. There were four IRS Group I, six Group II, four Group III, and two Group IV patients receiving irradiation. Tumor grade included seven Grade II and nine Grade III lesions. TMN staging identified eight T1 and eight T2 lesions. Follow-up has ranged from 14 to 117 months (med = 33 months). All IRS Group I patients had documented local control. Five of six IRS Group II and 4/4 Group III patients have had documented local control at last follow-up. IRS Group IV patients had either local control tumor stabilization (n = 1) or evidence of tumor regression (n = 1) at autopsy. Complications following irradiation include wound dehiscence (n = 1), surgery to revise a painful scar (n = 1) extremity length discrepancy (n = 2), and femoral head avascular necrosis (n = 1). At last follow-up, 10 of 14 patients receiving curative intent irradiation remain alive. This review indicates questionable benefit to the addition of irradiation for patients with adequate surgical resection and having 'good' tumor characteristics (Grade I, II; IRS Group I, TMN T(1A), T(1B)). For lesions that have had incomplete resection or partial response to chemotherapy, there is evidence that irradiation may provide durable local control. The role of irradiation in those patients with IRS Group IV disease is at present confined to palliative roles until the time when more effective chemotherapy will mandate the decision to treat primary disease for curative measures.

AB - The role of irradiation in the management of synovial sarcoma (SS) in pediatric patients is evaluated. The review covers all children seen at St. Jude Children's Research Hospital between May 1969 and December 1992 with the diagnosis of soft tissue sarcoma, of the 37 patients with the subtype SS, 16 received irradiation for the management of primary site disease. There were four IRS Group I, six Group II, four Group III, and two Group IV patients receiving irradiation. Tumor grade included seven Grade II and nine Grade III lesions. TMN staging identified eight T1 and eight T2 lesions. Follow-up has ranged from 14 to 117 months (med = 33 months). All IRS Group I patients had documented local control. Five of six IRS Group II and 4/4 Group III patients have had documented local control at last follow-up. IRS Group IV patients had either local control tumor stabilization (n = 1) or evidence of tumor regression (n = 1) at autopsy. Complications following irradiation include wound dehiscence (n = 1), surgery to revise a painful scar (n = 1) extremity length discrepancy (n = 2), and femoral head avascular necrosis (n = 1). At last follow-up, 10 of 14 patients receiving curative intent irradiation remain alive. This review indicates questionable benefit to the addition of irradiation for patients with adequate surgical resection and having 'good' tumor characteristics (Grade I, II; IRS Group I, TMN T(1A), T(1B)). For lesions that have had incomplete resection or partial response to chemotherapy, there is evidence that irradiation may provide durable local control. The role of irradiation in those patients with IRS Group IV disease is at present confined to palliative roles until the time when more effective chemotherapy will mandate the decision to treat primary disease for curative measures.

KW - irradiation

KW - soft tissue sarcoma

KW - synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0029883807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029883807&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199604)26:4<264::AID-MPO9>3.0.CO;2-H

DO - 10.1002/(SICI)1096-911X(199604)26:4<264::AID-MPO9>3.0.CO;2-H

M3 - Article

VL - 26

SP - 264

EP - 267

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -